

**DRUG DISCOVERY TODAY****Editorial**

**Editor:** Steve Carney  
**Content Development Manager:** Pien van Spijker  
**Journal Manager:** Bharathi Sims  
**Publisher:** Fernanda Ogochi  
**Editorial Enquiries:**  
*Drug Discovery Today*  
 Elsevier  
 125 London Wall, London, EC2Y 5AS, UK  
 Tel: +44 (0) 20 8439 5525  
 Fax: +44 (0)1865 853067  
 Email: ddt@drugdiscoverytoday.com

**ADVISORY EDITORIAL BOARD**

**Jurgen Bajorath** *University of Bonn, Germany*  
**Walter Blackstock** *Experimental Therapeutics Centre, Singapore*  
**David Brayden** *University College Dublin, Ireland*  
**Paul Caron** *Integrated Profiling, USA*  
**David Cavalla** *Numedicus Ltd., UK*  
**David Clark** *Argenta Discovery, UK*  
**Dalia Cohen** *ALN Associates, USA*  
**Donald Daley** *Argenta Discovery, UK*  
**Sean Ekins** *Collaborations in Chemistry, USA*  
**Hans-Peter Fischer** *GeneData, Switzerland*  
**Peter Ghazal** *University of Edinburgh, UK*  
**Christopher M. Hill** *Merck, USA*  
**Nick Hird** *Takeda Chemical Industries, Japan*  
**Enoch Huang** *Pfizer, USA*  
**Thomas Joos** *University of Tuebingen, Germany*  
**Vincent H.L. Lee** *Chinese University of Hong Kong, China*  
**David Lewin** *Yale University, USA*  
**Christopher A. Lipinski** *Meliior Discovery, USA*  
**Lorenz Mayr** *AstraZeneca, UK*  
**Nick Meanwell** *Bristol-Myers Squibb, USA*  
**BK Muralidhara** *AstraZeneca, USA*  
**Mark Murcko** *Disruptive Biomedical, LLC, USA*  
**Fajun Nan** *Shanghai Institute of Materia Medica, China*  
**Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge*  
**Gitte Neubauer** *Cellzome, Germany*  
**Eric Neumann** *Clinical Semantics Group Consulting, USA*  
**Tim Peakman** *UK Biobank, UK*  
**Norton Peet** *Microbiotix, Inc., USA*  
**Manuel Peitsch** *Swiss Institute of Bioinformatics, Switzerland*  
**Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA*  
**Janice Reichert** *Reichert Biotechnology Consulting LLC, MA, USA*  
**John Reidhaar-Olson** *Albert Einstein College of Medicine, New York, USA*  
**Mike Romanos** *Crescendo Biologics, Cambridge, UK*  
**Raymond C. Rowe** *Intelligensys, UK*  
**Andreas Russ** *University of Oxford, UK*  
**Esther Schmid** *EFS Strategy and Business Consulting, UK*  
**Jonathan Sheldon** *Translational Medicine, Oracle, UK*  
**Michael Snyder** *Stanford University, USA*  
**Susie Stephens** *Johnson & Johnson, USA*  
**Robert Strausberg** *Ludwig Institute for Cancer Research, New York, USA*  
**Yuichi Sugiyama** *University of Tokyo, Japan*  
**David Szymkowski** *Xencor, USA*  
**Nick Terrett** *Ensemble Discovery, USA*  
**Vladimir Torchilin** *Northeastern University, Boston, USA*  
**Mark Whittaker** *Evotec OAI, UK*  
**Hans Winkler** *Janssen Pharmaceutica, Belgium*  
**Limsoon Wong** *National University of Singapore*  
**X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

# DRUG DISCOVERY TODAY

## REVIEWS (continued)

### 1000 Bugs, drugs, and cancer: can the microbiome be a potential therapeutic target for cancer management?

*Biying Chen, Guangye Du, Jiahui Guo and Yanjie Zhang*

### INFORMATICS

### 1010 Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases

*Rebekah H. Griesenauer, Constantino Schillebeeckx and Michael S. Kinch*

### POST SCREEN

### 1017 Development of long-acting recombinant glycoprotein hormones by increasing the carbohydrate content

*Fuad Fares and Naiel Azzam*

### 1023 E-drug delivery: a futuristic approach

*Khushwant S. Yadav, Sonali Kapse-Mistry, G.J. Peters and Y.C. Mayur*

### 1031 Strategies for the discovery of biased GPCR ligands

*Marcel Bermudez, Trung Ngoc Nguyen, Christian Omieczynski and Gerhard Wolber*

### 1038 Amino acids at the intersection of nutrition and insulin sensitivity

*Xueli Zhang, Hua Shao and Xiao Zheng*

### 1044 Anticancer activity of palladium-based complexes against triple-negative breast cancer

*Martin Vojtek, Maria P.M. Marques, Isabel M.P.L.V.O. Ferreira, Hélder Mota-Filipe and Carmen Diniz*

### 1059 Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing

*Katarzyna Regulaska, Miłosz Regulski, Bartosz Karolak, Marek Murias and Beata Stanisiz*

#### FORTHCOMING ARTICLES:

#### Müller cells as a target for retinal therapy.

*By Joke Devoldere, Karen Peynshaert, Stefaan C. De Smedt, Katrien Remaut.*

#### Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.

*By Astrid Subrizi, Eva M. del Amo, Viktor Korzhakov-Vlakh, Tatiana Tennikova, Marika Ruponen and Arto Urtti.*

#### Modified cells as potential ocular drug delivery systems.

*By Tatiana Tennikova<sup>1</sup> and Arto Urtti*

#### Connexin43 hemichannels: a potential drug target for the treatment of diabetic retinopathy.

*By Odunayo O. Mugisho, Colin R. Green, Jie Zhang, Monica L. Acosta and Ilva D. Rupenthal.*